SANGAMO THERAPEUTICS INC (SGMO) Stock News

USA - Nasdaq - NASDAQ:SGMO - US8006771062 - Common Stock

0.5033 USD

0 (-0.16%)

Last: 12/9/2025, 8:00:02 PM

0.4989 USD

0 (-0.87%)

After Hours: 12/9/2025, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

SGMO Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

19 days ago - By: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease

a month ago - By: Benzinga - Mentions: NNVC REVB CYCN CNSP ...

12 Health Care Stocks Moving In Monday's After-Market Session

a month ago - By: Benzinga - Mentions: CCOI XRAY KMX GDEN

This CarMax Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

a month ago - By: The Motley Fool - Mentions: PFE

Sangamo (SGMO) Q3 2025 Earnings Call Transcript

a month ago - By: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call

a month ago - By: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results

3 months ago - By: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025

4 months ago - By: Zacks Investment Research

What Makes Sangamo (SGMO) a New Buy Stock

4 months ago - By: Zacks Investment Research - Mentions: CRVO

Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates

4 months ago - By: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

6 months ago - By: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

7 months ago - By: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results

7 months ago - By: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering

7 months ago - By: Zacks Investment Research - Mentions: ARMP

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates

7 months ago - By: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

7 months ago - By: Zacks Investment Research - Mentions: NVAX

Novavax (NVAX) Beats Q1 Earnings and Revenue Estimates

7 months ago - By: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Announces First Quarter 2025 Earnings Call

7 months ago - By: Sangamo Therapeutics, Inc.

Sangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry Disease

7 months ago - By: Zacks Investment Research - Mentions: RGNX

Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

7 months ago - By: Zacks Investment Research - Mentions: QGEN

Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

8 months ago - By: Sangamo Therapeutics, Inc.

Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)